应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
未开盘 03-18 16:08:04
4.190
+0.040
+0.96%
最高
4.480
最低
4.110
成交量
823.50万
今开
4.150
昨收
4.150
日振幅
8.92%
总市值
20.91亿
流通市值
20.91亿
总股本
4.99亿
成交额
3,525万
换手率
1.65%
流通股本
4.99亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
开拓药业-B(09939)：KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达到主要终点
智通财经 · 03-18 20:59
开拓药业-B(09939)：KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达到主要终点
港股异动 | 开拓药业-B(09939)早盘涨超5% 携手上美股份加速美白化妆品原料KT-939商业化
智通财经 · 03-18 09:36
港股异动 | 开拓药业-B(09939)早盘涨超5% 携手上美股份加速美白化妆品原料KT-939商业化
3月17日三博脑科跌6.85%，银河医药混合A基金重仓该股
证券之星 · 03-17 16:14
3月17日三博脑科跌6.85%，银河医药混合A基金重仓该股
医药板块震荡走强 三生国健涨超8%
人民财讯 · 03-17 10:36
医药板块震荡走强 三生国健涨超8%
白云山(00874)：广州医药应收账款资产支持专项计划资产支持证券挂牌转让获得上交所无异议函
智通财经网 · 03-16 18:27
白云山(00874)：广州医药应收账款资产支持专项计划资产支持证券挂牌转让获得上交所无异议函
3月16日爱迪特跌6.73%，银河医药混合A基金重仓该股
证券之星 · 03-16 16:28
3月16日爱迪特跌6.73%，银河医药混合A基金重仓该股
石药集团等在海南成立医药科技公司
人民财讯 · 03-16 11:18
石药集团等在海南成立医药科技公司
港股异动 | 开拓药业-B(09939)再涨超9% 携手孚诺医药研发KT-939原料美白祛斑化妆品
智通财经 · 03-16 10:43
港股异动 | 开拓药业-B(09939)再涨超9% 携手孚诺医药研发KT-939原料美白祛斑化妆品
新股消息 | 普祺医药拟港股上市 中国证监会要求补充说明历史建设工程瑕疵的整改情况等事项
智通财经 · 03-13
新股消息 | 普祺医药拟港股上市 中国证监会要求补充说明历史建设工程瑕疵的整改情况等事项
医药板块周线回调，关注港股通创新药ETF易方达（159316）、创新药ETF易方达（516080）等产品布局机会
证券之星 · 03-13
医药板块周线回调，关注港股通创新药ETF易方达（159316）、创新药ETF易方达（516080）等产品布局机会
行业观察 | IPO浪潮下医药支付赛道“热”度升温：镁信健康迎来能力验证期
财经杂志 · 03-13
行业观察 | IPO浪潮下医药支付赛道“热”度升温：镁信健康迎来能力验证期
“十五五”开局，恒瑞医药将站在新起点加速推进医药创新
制药网 · 03-13
“十五五”开局，恒瑞医药将站在新起点加速推进医药创新
劲方医药-B盘中异动 早盘股价大跌5.09%报29.460港元
市场透视 · 03-13
劲方医药-B盘中异动 早盘股价大跌5.09%报29.460港元
开拓药业-B(09939)与孚诺医药订立战略合作协议 推动功效性化妆品原料KT-939的市场转化和拓展
智通财经 · 03-12
开拓药业-B(09939)与孚诺医药订立战略合作协议 推动功效性化妆品原料KT-939的市场转化和拓展
开拓药业与浙江福诺医药达成战略合作协议
美股速递 · 03-12
开拓药业与浙江福诺医药达成战略合作协议
步长制药最新公告：全资子公司山东丹红拟与鸿育医药签署技术转让与科研合作合同
证券之星 · 03-12
步长制药最新公告：全资子公司山东丹红拟与鸿育医药签署技术转让与科研合作合同
中赋科技：全资子公司鼎赋医药正处于业务筹备阶段
证券之星 · 03-12
中赋科技：全资子公司鼎赋医药正处于业务筹备阶段
3月12日热景生物跌6.23%，汇添富创新医药混合A基金重仓该股
证券之星 · 03-12
3月12日热景生物跌6.23%，汇添富创新医药混合A基金重仓该股
港股异动 | 开拓药业-B(09939)再涨近5% KX-826三期临床顶线数据本月内将揭露
智通财经 · 03-12
港股异动 | 开拓药业-B(09939)再涨近5% KX-826三期临床顶线数据本月内将揭露
华昊中天医药-B(02563.HK)拟3月25日举行董事会会议审批全年业绩
中金财经 · 03-11
华昊中天医药-B(02563.HK)拟3月25日举行董事会会议审批全年业绩
加载更多
公司概况
公司名称：
开拓药业-B
所属市场：
SEHK
上市日期：
--
主营业务：
开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。
发行价格：
--
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":4.19,"timestamp":1773821284030,"preClose":4.15,"halted":0,"volume":8235000,"delay":0,"changeRate":0.009638554216867478,"floatShares":499000000,"shares":499000000,"eps":-0.360537,"marketStatus":"未开盘","change":0.04,"latestTime":"03-18 16:08:04","open":4.15,"high":4.48,"low":4.11,"amount":35248905,"amplitude":0.089157,"askPrice":4.19,"askSize":38500,"bidPrice":4.18,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-0.367,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773883800000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":4.15,"openAndCloseTimeList":[[1773797400000,1773806400000],[1773810000000,1773820800000]],"volumeRatio":1.194958,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2620256274","title":"开拓药业-B(09939)：KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256274","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620256274?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:59","pubTimestamp":1773838785,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开拓药业-B 发布公告，其自主研发、潜在同类首创的 KX-826酊1.0%治疗脱发的关键性临床试验III期阶段已获得顶线数据。KX-826作为公司目前进展最快的外用创新药物之一，自开发以来已在中国和美国完成针对男性及女性的多项用于治疗脱发的临床试验，并表现出优异的有效性及安全性。该药物和KX-826均有望作为一种治疗雄激素性脱发的全新疗法，为广大脱发患者提供了更安全且有效的治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","BK4134","09939","BK1574","BK1515"],"gpt_icon":0},{"id":"2620400598","title":"港股异动 | 开拓药业-B(09939)早盘涨超5% 携手上美股份加速美白化妆品原料KT-939商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2620400598","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620400598?lang=zh_cn&edition=full","pubTime":"2026-03-18 09:36","pubTimestamp":1773797776,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开拓药业-B(09939)早盘涨超5%，截至发稿，涨5.54%，报4.38港元，成交额199.09万港元。消息面上，开拓药业公告，其全资附属公司与上美股份(02145)订立化妆品领域附带排他条款的战略合作框架协议，双方将围绕开拓药业旗下美白祛斑功效性化妆品原料KT-939展开深度合作，协同推进原料与产品注册，加速其商业化落地，共同打造具有行业影响力的“地表最强国产美白剂”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02145","LU0541502299.USD","LU0541501648.USD","KT","VXUS","BK1207","BK4115","BK4588","BK1574","BK4585","LU2242644610.SGD","LU0502904849.HKD","09939","SG9999004220.SGD","BK1515","LU0455707207.USD"],"gpt_icon":0},{"id":"2620444088","title":"3月17日三博脑科跌6.85%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620444088","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620444088?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:14","pubTimestamp":1773735275,"startTime":"0","endTime":"0","summary":"证券之星消息，3月17日三博脑科跌6.85%，收盘报75.92元，换手率14.27%，成交量22.96万手，成交额17.94亿元。重仓三博脑科的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6204，较上一交易日下跌0.39%，近一年上涨18.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700027165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK0236","301293","09939","159938","BK1574"],"gpt_icon":0},{"id":"2620541482","title":"医药板块震荡走强 三生国健涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620541482","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620541482?lang=zh_cn&edition=full","pubTime":"2026-03-17 10:36","pubTimestamp":1773714990,"startTime":"0","endTime":"0","summary":"人民财讯3月17日电，医药板块震荡走强，三生国健涨超8%，苑东生物、荣昌生物、海思科、泽璟制药、君实生物等涨幅居前。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674269731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1574","09939","BK0239","159938","BK1161","688336"],"gpt_icon":0},{"id":"2619345179","title":"白云山(00874)：广州医药应收账款资产支持专项计划资产支持证券挂牌转让获得上交所无异议函","url":"https://stock-news.laohu8.com/highlight/detail?id=2619345179","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619345179?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:27","pubTimestamp":1773656854,"startTime":"0","endTime":"0","summary":"白云山(00874)发布公告，2026 年 3 月 13 \n日，本公司收到兴证证券资产管理有限公司(“兴证资管”)转发的上海证券交易所(“上交所”)《关于对兴证圆融-广州医药应收账款 5-9 \n期资产支持专项计划资产支持证券挂牌转让无异议的函》(上证函[2026]830 号)(“《无异议函》”)，现将相关情况公告如下：","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0097","BK0028","BK1161","BK0012","BK0096","BK1197","BK1574","BK1515","BK0188","BK0183","09939","600332","BK0196","BK0239","161027","BK0070","BK1191","BK1521","159938","00874","BK1606","BK0175"],"gpt_icon":0},{"id":"2619453526","title":"3月16日爱迪特跌6.73%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619453526?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:28","pubTimestamp":1773649719,"startTime":"0","endTime":"0","summary":"证券之星消息，3月16日爱迪特跌6.73%，收盘报80.47元，换手率11.71%，成交量8.43万手，成交额6.77亿元。重仓爱迪特的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6228，较上一交易日上涨0.66%，近一年上涨20.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600021741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK1161","159938","BK1574","BK1515","09939","301580"],"gpt_icon":0},{"id":"2619535433","title":"石药集团等在海南成立医药科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2619535433","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619535433?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:18","pubTimestamp":1773631098,"startTime":"0","endTime":"0","summary":"人民财讯3月16日电，企查查APP显示，近日，石药细胞谷（海南）医药科技有限公司成立，法定代表人为肖本景，注册资本2000万元，经营范围包含医疗服务；药品生产；生活美容服务；医学研究和试验发展；人体干细胞技术开发和应用等。企查查股权穿透显示，该公司由石药控股集团有限公司、深圳细胞谷生物医药有限公司等共同持股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163672895546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1226287529.USD","IE0008368742.USD","IE00B031HY20.USD","LU0314109678.HKD","01093","LU0315179316.USD","LU1960683339.HKD","LU0072913022.USD","LU1226287875.USD","LU1152091168.USD","LU0067412154.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","09939","LU1328277881.USD","LU1993786604.SGD","IE0008369823.USD","159938","LU0880133367.SGD","LU2039709279.SGD","LU0140636845.USD","LU1226288253.USD","BK1161","SG9999004220.SGD","HK0000165453.HKD","LU1813983027.USD","BK1191","LU1951186391.HKD","IE00B543WZ88.USD","LU1226288170.HKD","LU1152091754.HKD","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1226287792.SGD","LU0501845795.SGD","LU0326950275.SGD","LU1807302812.USD","BK1574","BK1521","BK1515"],"gpt_icon":0},{"id":"2619843838","title":"港股异动 | 开拓药业-B(09939)再涨超9% 携手孚诺医药研发KT-939原料美白祛斑化妆品","url":"https://stock-news.laohu8.com/highlight/detail?id=2619843838","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619843838?lang=zh_cn&edition=full","pubTime":"2026-03-16 10:43","pubTimestamp":1773628985,"startTime":"0","endTime":"0","summary":"消息面上，开拓药业发布公告，全资附属公司与孚诺医药签订战略合作协议，双方将联合开发以开拓药业创新原料KT-939为核心的美白祛斑功效性化妆品，为皮肤色素沉着改善及黄褐斑治疗提供全新辅助方案。公司计划利用KT-939功效性化妆品原料业务所产生的现金流，为核心产品KX-826及GT20029及其他管线产品的开发及商业化提供资金支持。凭借扎实的临床数据，KX-826成功获得国际化妆品成分INCI命名，成为合规化妆品原料。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999004220.SGD","LU0541501648.USD","BK4585","BK4115","BK4588","BK1161","159938","BK1574","KT","BK1515","09939","LU0541502299.USD","VXUS"],"gpt_icon":0},{"id":"2619194221","title":"新股消息 | 普祺医药拟港股上市 中国证监会要求补充说明历史建设工程瑕疵的整改情况等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194221","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619194221?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:56","pubTimestamp":1773402996,"startTime":"0","endTime":"0","summary":"中国证监会国际司共对8家企业出具补充材料要求，其中，要求普祺医药补充说明历史建设工程瑕疵的整改情况等事项。据港交所1月21日披露，北京普祺医药科技股份有限公司向港交所主板递交上市申请书，中信证券、民银资本为联席保荐人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4588","VXUS","159938","BK1574","BK4585","09939","BK1161"],"gpt_icon":0},{"id":"2619719965","title":"医药板块周线回调，关注港股通创新药ETF易方达（159316）、创新药ETF易方达（516080）等产品布局机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619719965?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:55","pubTimestamp":1773399353,"startTime":"0","endTime":"0","summary":"本周，中证创新药产业指数下跌0.8%，沪深300医药卫生指数下跌1.0%，中证生物科技主题指数下跌1.1%，恒生港股通创新药指数下跌3.0%，中证港股通医药卫生综合指数下跌3.4%。Wind数据显示，截至昨日，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)和创新药ETF易方达(516080，联接基金A/C：019666/019667)本周分别获3600万元和2100万元资金净流入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026031300033395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","516080","BK1574","520880","09939","159938","BK1161","159316"],"gpt_icon":0},{"id":"2619116071","title":"行业观察 | IPO浪潮下医药支付赛道“热”度升温：镁信健康迎来能力验证期","url":"https://stock-news.laohu8.com/highlight/detail?id=2619116071","media":"财经杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619116071?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:15","pubTimestamp":1773393300,"startTime":"0","endTime":"0","summary":"镁信健康这样的平台型企业也迎来了真正的能力验证期…镁信健康正诞生于这一张力之中。更重要的是，在赛道尚未形成共识之前，镁信健康已经率先完成了多项行业探索。在外界看来，这一轮监管似乎对以“医+药+险”融合见长的平台企业形成压力，甚至一度有人误以为镁信健康成为“被针对的对象”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"weixin_highlight","url":"http://mp.weixin.qq.com/s?__biz=MjM5NDU5NTM4MQ==&mid=2653720028&idx=2&sn=e918b9c339786f9381f07a732a86aa6e&chksm=bc49220a937417f81821b283bc8cbe887caf17915cad5ad3c9f277597fa83d6925fe452f7700&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NDU5NTM4MQ==&mid=2653720028&idx=2&sn=e918b9c339786f9381f07a732a86aa6e&chksm=bc49220a937417f81821b283bc8cbe887caf17915cad5ad3c9f277597fa83d6925fe452f7700&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","BK1161","BK1515","09939","159938"],"gpt_icon":0},{"id":"2619161081","title":"“十五五”开局，恒瑞医药将站在新起点加速推进医药创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2619161081","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619161081?lang=zh_cn&edition=full","pubTime":"2026-03-13 10:23","pubTimestamp":1773368583,"startTime":"0","endTime":"0","summary":"2026年是“十五五”开局之年，站在新起点，恒瑞医药将紧扣\"十五五\"规划纲要要求，加速推进医药创新。作为国内大型药企，恒瑞医药以创新转型为核心引擎，已构建起以自主原研为驱动的产品与技术体系，公司已有20多款1类创新药获批上市。在肿瘤方面，恒瑞医药形成覆盖七大高发癌种、肿瘤支持治疗及多个重大未满足临床需求领域的系统化布局。如2025年上半年，恒瑞医药创新药销售及许可收入占比突破60%，占公司营业收入比重60.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031310252197b06142&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031310252197b06142&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","01276","BK1191","09939","BK1574","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU0359201612.USD","BK1515","BK1161"],"gpt_icon":0},{"id":"2619193164","title":"劲方医药-B盘中异动 早盘股价大跌5.09%报29.460港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619193164?lang=zh_cn&edition=full","pubTime":"2026-03-13 09:35","pubTimestamp":1773365717,"startTime":"0","endTime":"0","summary":"2026年03月13日早盘09时35分，劲方医药-B股票出现异动，股价快速下挫5.09%。截至发稿，该股报29.460港元/股，成交量2.32万股，换手率0.01%，振幅5.48%。资金方面，该股资金流入0港元，流出57.0132万港元。劲方医药-B股票所在的药品行业中，整体跌幅为0.08%。其相关个股中，海西新药、中智药业、四环医药涨幅较大，振幅较大的相关个股有联邦制药、长风药业、宝济药业-B，振幅分别为5.36%、3.92%、3.51%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031309351797b0493e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031309351797b0493e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","02595","BK1515","BK1161"],"gpt_icon":0},{"id":"2618013255","title":"开拓药业-B(09939)与孚诺医药订立战略合作协议 推动功效性化妆品原料KT-939的市场转化和拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2618013255","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618013255?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:44","pubTimestamp":1773319483,"startTime":"0","endTime":"0","summary":"根据合作协议，苏州开拓将向孚诺医药提供KT-939原料，并授权其在中国大陆境内开发、生产和销售以KT-939为核心活性成分的美白祛斑产品，以辅助其核心产品之一孚立美乳膏治疗黄褐斑。本次与孚诺医药订立合作协议，旨在建立长期稳定的战略合作关系，充分发挥双方在创新原料研发与皮肤外用产品开发领域的互补优势，推动功效性化妆品原料KT-939的市场转化和拓展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","BK1161","LU0541502299.USD","KT","SG9999004220.SGD","BK1574","BK4115","LU0541501648.USD","09939"],"gpt_icon":0},{"id":"1111398770","title":"开拓药业与浙江福诺医药达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1111398770","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111398770?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:42","pubTimestamp":1773319333,"startTime":"0","endTime":"0","summary":"开拓药业宣布，其子公司已与浙江福诺医药正式签署战略合作协议，双方将在医药领域展开深度合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2618510136","title":"步长制药最新公告：全资子公司山东丹红拟与鸿育医药签署技术转让与科研合作合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2618510136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618510136?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:59","pubTimestamp":1773313191,"startTime":"0","endTime":"0","summary":"步长制药(603858.SH)公告称，公司全资子公司山东丹红拟与杭州鸿育医药科技有限公司就益气活血解郁颗粒临床前研究技术转让及其新药开发事宜签署《技术转让与科研合作合同》。由于医药产品具有高科技、高风险、高附加值的特点，产品从研制、临床试验报批到投产的周期长、环节多，容易受到一些不确定性因素的影响。敬请广大投资者谨慎决策，注意防范投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200031932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK1515","BK0196","159938","BK1574","BK1161","09939","BK0239"],"gpt_icon":0},{"id":"2618801111","title":"中赋科技：全资子公司鼎赋医药正处于业务筹备阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2618801111","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618801111?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:36","pubTimestamp":1773308181,"startTime":"0","endTime":"0","summary":"证券之星消息，中赋科技(300692)03月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司控股鼎赋医药是否已经开展实际业务？其控股的子公司安徽中赋灵源生物技术有限公司，跟灵赋生物有关联吗？中赋科技回复：尊敬的投资者您好，全资子公司鼎赋医药正处于业务筹备阶段，安徽中赋灵源生物技术有限公司为鼎赋医药全资子公司，计划开展生物医药相关业务，具体请以公司披露的相关公告为准。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200030948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0218","159938","BK1574","09939","BK1161","BK1515","300692","BK0150","BK0135"],"gpt_icon":0},{"id":"2618814341","title":"3月12日热景生物跌6.23%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618814341","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618814341?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:21","pubTimestamp":1773303666,"startTime":"0","endTime":"0","summary":"证券之星消息，3月12日热景生物跌6.23%，收盘报128.0元，换手率2.75%，成交量2.55万手，成交额3.27亿元。重仓热景生物的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共53家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为72.69亿元，最新净值1.6674，较上一交易日下跌1.64%，近一年上涨26.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200025987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","BK1574","688068","09939","BK1161","BK0239"],"gpt_icon":0},{"id":"2618018860","title":"港股异动 | 开拓药业-B(09939)再涨近5% KX-826三期临床顶线数据本月内将揭露","url":"https://stock-news.laohu8.com/highlight/detail?id=2618018860","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618018860?lang=zh_cn&edition=full","pubTime":"2026-03-12 14:32","pubTimestamp":1773297150,"startTime":"0","endTime":"0","summary":"消息面上，近日，开拓药业在投资平台表示，其自主研发的外用雄激素受体拮抗剂KX-826，1.0%酊剂治疗男性雄激素性脱发的Ⅲ期临床顶线数据，将于2026年3月中下旬正式披露。凭借扎实的临床数据，KX-826成功获得国际化妆品成分INCI命名，成为合规化妆品原料。公开资料显示，2026年1月，公司与德开医药签订防脱泡沫剂国内独家销售协议，接入覆盖全国的成熟销售网络，为药物上市后的快速市场渗透提前布局，进一步拓展了KX-826未来商业化布局空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","BK4585","09939","BK1161","BK1515","VXUS"],"gpt_icon":0},{"id":"2618458709","title":"华昊中天医药-B(02563.HK)拟3月25日举行董事会会议审批全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618458709","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618458709?lang=zh_cn&edition=full","pubTime":"2026-03-11 18:07","pubTimestamp":1773223625,"startTime":"0","endTime":"0","summary":"格隆汇3月11日丨华昊中天医药-B(02563.HK)宣布，公司将于2026年3月25日(星期三)举行董事会会议，藉以(其中包括)(i)考虑及酌情批准公司及其附属公司截至2025年12月31日止年度的综合全年业绩及其刊发；(ii)考虑派付末期股息建议(如有)；及(iii)处理任何其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260311/32060614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1515","159938","02563","09939","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.0771},{"period":"1month","weight":0.5236},{"period":"3month","weight":1.1937},{"period":"6month","weight":0.5634},{"period":"1year","weight":2.5508},{"period":"ytd","weight":1.1378}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0255},{"period":"3month","weight":0.0207},{"period":"6month","weight":-0.0196},{"period":"1year","weight":0.0519},{"period":"ytd","weight":0.0154}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.5,"avgChangeRate":0.164284},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}